Introduction
Apoptosis is a peculiar mode of cell death, regulating several physiological processes and also involved in diverse pathological conditions, defined by either deficient or excessive apoptosis. As far as cancer disease is concerned, compelling evidence indicates that a deficient apoptosis -due to alterations at different levels -may lead to tumor initiation, progression and metastases; on the other hand, the major goal of most cytotoxic anticancer agents is to commit tumor cells to apoptosis.
Cisplatin (cis-platinum(II) diammine dichloride (CDDP)) is a DNA-damaging agent widely used in anticancer therapy. Its cytotoxic effect is a complex process extending from initial drug entry into cells to the final stages of apoptosis (see, for a review, Siddik, 2003) . It is well documented that the level and persistence of cisplatin/DNA adducts correlate directly with cytotoxicity, but little is known how cellular signaling from the DNA lesions ultimately leads to apoptosis, and, as a consequence, how the frequent intrinsic or acquired resistance occurs.
Our aim in the last few years was to characterize some biochemical mechanisms of the cisplatin-induced apoptosis in human melanoma cells (Del Bello et al., 2001 . We have previously demonstrated (Del Bello et al., 2004) a clear involvement of the mitochondrial pathway, that is, redistribution of cytochrome c from mitochondria to cytosol and activation of caspases, both those directly forming the apoptosome (caspase-9) and those downstream activated (caspase-3 and -7). However, conditions affording the complete activity inhibition of all the above caspases do not abrogate several apoptosis-associated events, that is, cell detachment from the monolayer, the proteolytic cleavage of crucial substrates such as poly(ADP-ribose) polymerase (PARP) and lamin B, and the typical apoptotic nuclear morphology; these results, suggesting that the point of no return for cisplatin toxicity is not placed in the apoptosome formation, have prompted us to investigate the possible contribution played by different effector mechanisms, in particular by calpains.
Calpains are a family of Ca 2 þ -dependent neutral cysteine proteases. Fifteen gene products of the family are presently known in mammals (see, for a review, Sorimachi et al., 1997) , among which two isoenzymes, m-calpain (calpain I) and m-calpain (calpain II), termed 'conventional' calpains, are ubiquitously expressed in human tissues. These conventional calpains are heterodimers consisting of a specific catalytic subunit of about 80 kDa and a common regulatory subunit p28 (calpain 4), all being characterized by a C-terminal Ca 2 þ -binding domain. Besides calcium, several mechanisms can directly or indirectly modulate the activity of conventional calpains, such as interaction with the endogenous inhibitor calpastatin or other regulatory proteins, Ser/ Thr phosphorylation, limited autoproteolysis and association with specific membrane phospholipids. The proteolytic activity of calpains results in a limited cleavage of specific proteins, irreversibly modified in their functions and is involved in a number of cellular events, including cell proliferation and differentiation, gene expression, cytoskeleton reorganization and motility, and apoptosis (Sorimachi et al., 1997; Sato and Kawashima, 2001; Goll et al., 2002; Suzuki et al., 2004) . The role of calpains in apoptotic cell death is still poorly understood. There are contrasting data whether calpain and caspases independently act in different apoptotic pathways (Li et al., 2000) , or they act in a cooperative manner (Knepper-Nicolai et al., 1998; Gao and Dou, 2000; Nakagawa and Yuan, 2000) . In the latter case, calpain activation can be consequent to caspase activation (Porn-Ares et al., 1998; Wang et al., 1998) , or it can play an initiating role (Waterhouse et al., 1998; Wood et al., 1998; Gao and Dou, 2000; Daniel et al., 2003) .
The aim of the present study was to further investigate the cisplatin-induced apoptotic machinery in melanoma cells, with particular emphasis on (i) calpain activation and its possible link with alterations of Ca 2 þ homeostasis, (ii) the role of calpain in apoptosis, possibly related to p53 upregulation and (iii) the functional/ temporal correlations between the calpain system and the effector caspases-3 and -7.
Results

Calpain activity is increased early in preapoptotic cells
It is well established that, along with calcium requirement, calpain molecules perform their activity after translocation from cytosol to membranes and into the lumen of organelles (Molinari and Carafoli, 1997) , in particular, endoplasmic reticulum and Golgi apparatus. Furthermore, in cell lysates, where the subcellular structure is disrupted, the endogenous inhibitor calpastatin rapidly and artificially associates to active calpain (Han et al., 1999) . In the light of such considerations, to avoid the invasive procedure of cellular lysates, we performed calpain test in intact cells, by using two different synthetic fluorescent and cell-permeable oligopeptides, both substrates of the conventional calpains. In Figure 1a , the time-course of calpain activity, measured by the fluorescent substrate t-Boc-Leu-Met-CMAC (BOC), is reported. Calpain activity in cisplatintreated cells compared to control cells at the same incubation times is early and progressively increases from 12 to 24-48 h of treatment, in still-adhering cells. As expected, in samples co-treated with two different calpain inhibitors, MDL 28170 and calpeptin, the increase of calpain activity is fully inhibited until control levels. The proteolytic calpain activity of frankly apoptotic, detached cells (48 h) is not shown, as this assay proved to be not reliable in this specific cellular condition, as explained below. The BOC substrate indeed acts in a peculiar manner, which has not received enough consideration in the literature. CMAC -the product of BOC proteolysis -needs the enzymatic conjugation (via glutathione (GSH)-transferase) to (Rosser et al., 1993) . In fact, cisplatin treatment induces a dramatic GSH depletion in frankly apoptotic cells, while such depletion is much less evident in still adhering cells at 48 h and even absent at 24 h (Table 1) . A marked depletion of intracellular GSH has been described in a number of different models of apoptosis (Ghibelli et al., 1995; Macho et al., 1997) , where GSH loss is consequent to an accelerated efflux via specific GSH carriers (Van den Dobbelsteen et al., 1996; Ghibelli et al., 1998; Trompier et al., 2004 To confirm calpain activation in cisplatin-treated cells and to gain information about the population of frankly apoptotic cells, we carried out the same test in intact cells using a fluorescent substrate: N-succ-Leu-Tyr-AMC (Succ) (Figure 1b) . We obtained very similar results, confirming a significant increase of calpain activity at 48 h in still adhering cells, which is even more evident in detached cells. To further confirm calpain activation, in a separate set of experiments we measured its enzymatic activity by both substrates (BOC and Succ) in the presence of a third more specific calpain inhibitor, PD 150606, reported to not act on cathepsin and proteasome. A significant activity inhibition was observed in treated, still adhering cells, whereas such inhibition was minor in detached apoptotic cells (Figure 1c ). m-Calpain protein is consumed during cisplatin treatment Besides to its catalytic activity, we have also evaluated by Western blot analysis the cisplatin-induced changes of m-calpain protein (Figure 2 ). At 48 h of treatment, where the calpain activity is increased over control cells, a mild decrease of the small (regulatory) subunit (p28) is observed in treated, still adhering cells compared to control cells; in frankly apoptotic detached cells, p28 Role of calpain in cisplatin-induced apoptosis and p53 status B Del Bello et al almost disappeared. The latter event, at least in part, seems to be a caspase-3/-7-mediated proteolysis, as suggested by the bland sparing of the full-length protein by ac-Asp-Glu-Val-Asp-CHO (DEVD-CHO) ( Figure 2a ). Both calpain inhibitors, while not recovering p28 protein in floating cells, constantly increase it up to control levels in adhering cells. m-Calpain large (catalytic) subunit is progressively decreased from 12 to 48 h of cisplatin treatment, such consumption being even more marked in the detached cells at 36 h (few apoptotic cells) and 48 h (Figure 2b and c).
Intracellular Ca 2 þ imbalance occurs only in the late stages Given the requirement for calpain activation, at least in vitro, of an intracellular Ca 2 þ increase, we examined the effect of cisplatin poisoning on cellular Ca 2 þ homeostasis (Figure 3 (Figure 3b ). Similarly, no calcium imbalance is seen after 3, 6, 12 and 24 h of treatment compared to control cells (Figure 3a and b) .
As expected, no change in calpain activity is observed in the presence of the intracellular calcium chelator 1,2-bis-(o-Aminophenoxy)ethane-N,N,N 0 ,N 0 -tetra-acetic acid tetra(acetoxymethyl) ester (BAPTA-AM) (Figure 4) . Consistently, no protection from cell detachment and no decrease in caspase-3/-7 activity are observed (data not shown).
Inhibition of calpain activity decreases caspase-3/-7 activity and cell detachment As reported previously (Del Bello et al., 2001 , caspase-3/-7 enzymatic activity is remarkably increased in cisplatin-treated cells at 48 h, and, as expected, fully inhibited by the co-treatment with ac-DEVD-CHO. Now we show that under caspase-3/-7 inhibition calpain activity is almost unchanged, even if a slight trend toward an increased activity is observed ( Figure 5 ). On the contrary, in the presence of the calpain inhibitors MDL 28170 and calpeptin, caspase-3/-7 activity is significantly lower, being almost halved compared to cisplatin-treated cells. Such decrease can be considered a true protective effect, as underlined by the percentage of Role of calpain in cisplatin-induced apoptosis and p53 status B Del Bello et al cells detached from the monolayer, which is significantly diminished ( Table 2) . We have previously demonstrated that the rate of cell detachment strictly mirrors the percentage of nuclei with an apoptotic morphology (Del Bello et al., 2001 . When MDL 28170 is added 24 h after cisplatin treatment (i.e. in already committed cells), the protective effect is markedly reduced (Table 2) , thus confirming that calpain activation in an early event in cisplatin-induced apoptosis. The co-treatment with the calpain inhibitor PD 150606 gives similar (even if milder) results on caspase-3/-7 activation and cell detachment (Table 2) . In separate experiments, three different unselected human melanoma cell lines have also been induced to apoptosis by cisplatin: a comparable protective effect is obtained by co-treatment with MDL 28170 and, similarly, with calpeptin (Table 3) .
Inhibition of calpain activity decreases p53 levels in committed cells but spares p53 breakdown in apoptotic cells As expected for a cisplatin-sensitive cell line, a marked upregulation of p53 protein is observed at 24 h of treatment ( Figure 6 ). Interestingly, at this time, a significative reduction of such p53 induction in samples co-treated with the calpain inhibitors MDL 28170 or calpeptin is observed. At culture times longer than 24 h, the cellular context becomes more complex, since a growing amount of apoptotic cells is produced by cisplatin. For this reason, at 48 h of treatment, adhering and floating cells were separately collected and analysed (Figure 7 ): in still adhering cells, showing minor signs of Cisplatin 5 mg/ml, 72 h of treatment.
c Cisplatin 1 mg/ml, 48 h of treatment. MDL 28170 and calpeptin (50 mM both) were added at 0 time. Role of calpain in cisplatin-induced apoptosis and p53 status B Del Bello et al cell death, p53 is significantly induced by cisplatin, consistently with the previous experimental times; on the contrary, in frankly apoptotic detached cells, a remarkable decrease of full-length p53 is evident, concomitantly with the occurrence of two immunoreactive fragments: a larger one (barely detectable in most experiments) with an apparent molecular weight of E40 kDa, and a smaller one (a prominent band in all experiments) with an apparent molecular weight of E26 kDa. The former p53 fragment, which likely corresponds to the p40 peptide previously demonstrated (Molinari et al., 1996; Okorokov and Milner, 1997) in in vitro models, is equally prevented in the presence of caspase-3/-7 inhibitor and calpain inhibitors; the latter p53 fragment, described here for the first time in vivo, proves to be a calpain-specific cleavage product, significantly spared only in samples co-treated with the calpain inhibitors MDL 28170 and calpeptin. In each case, an almost complete recovery of the full-length p53 is observed, compared to the unproteolysed sample of still adhering cells.
Discussion
The evidence for calpain activation has been mainly concerned with the oncotic cell death and the physiopathology of neuronal cells. In the last decade, an increasing interest has also focused calpain involvement during tumor cells apoptosis, the results showing a promoting or a protective role depending on the experimental model studied, and particularly depending on the concomitant involvement of the caspase machinery; the two protease systems, in fact, are proved to cross-talk (Neumar et al., 2003, and herein) . In the present study, we show that calpain activity is increased early in cisplatin-induced apoptosis of melanoma cells, this placing calpains upstream to effector caspases: whereas caspase-3/-7 activity is comparable to control levels until 30-33 h after cisplatin poisoning, calpain activity starts to raise at 12-24 h, as measured in intact cells. Interestingly, calpain activity increase matches with the protein level decrease of both m-calpain catalytic subunit (progressively during cisplatin treatment) and calpain regulatory subunit. Such a consumption, even in the absence of any detectable autoproteolytic fragment, is often regarded as a marker of calpain activation (Nath et al., 1996; Volbracht et al., 2005) . Strictly related to the controversial views on biochemistry of calpain activation (reviewed in Molinari and Carafoli, 1997; Kitagaki et al., 2000) , a constant debated problem is to reconcile the actual concentration of Ca 2 þ in the cytosol (nanomolar) with the high Ca 2 þ requirement of calpain in vitro; the Ca 2 þ concentrations giving half-maximal calpain activity in vitro, in fact, are 3-50 and 400-800 mM, for m-calpain and m-calpain, respectively (Goll et al., 2002) . Although high calcium concentrations are present in the presynaptic terminals of neurons and under specific pathological processes, much lower calcium concentrations should be sufficient to activate calpain in physiological conditions (Salamino et al., 1993; Zhang et al., 1996) . Thus, in addition to calcium, several mechanisms have been proposed, including association to specific membrane phospholipids (see for a review, Molinari and Carafoli, 1997) , interactions with activating proteins (Melloni et al., 1998 (Melloni et al., , 2000 , caspase-mediated degradation of the endogenous inhibitor calpastatin (Wang et al., 1998) and, more recently, extracellular signal-related kinase (ERK)-mediated phosphorylation (Glading et al., 2004) . In the present study, with the exception of late apoptotic detached cells, we do not detect any change in cytosolic and releasable reticular calcium throughout the time of cisplatin treatment, where calpain activity is early increased over control cells. We cannot rule out that calpain molecules anchored on membranes in proximity to calcium channels can experience calcium concentrations higher than those estimated in the bulk cytosol (Davies and Hallet, 1998) , thus calpains could be activated by transient calcium increases in such local microenvironments. In any case, under intracellular Ca 2 þ chelation by BAPTA-AM, neither changes in calpain activity, even in extremely damaged cells showing a marked calcium imbalance, nor protection from cell death are observed. Similarly to other experimental models (Arora et al., 1996; Han et al., 1999) , our results suggest that calcium fluxes do not play virtually any role in cisplatin-induced calpain activation and apoptosis of melanoma cells. The strong Ca 2 þ imbalance, occurring as an abrupt and late event only in detached cells, likely arises from an uncontrolled and irreversible proteolysis of Ca 2 þ -ATPases and/or ATP loss. This is at variance with a report (Mandic et al., 2002) , showing an early intracellular Ca 2 þ increase in melanoma cells after cisplatin treatment. An explanation for such a discrepancy could be the much higher cisplatin concentration used by the authors (20 versus 3.3 mM used in our experiments), which could directly affect critical thiols on proteins regulating Ca 2 þ ions homeostasis.
We have previously demonstrated that a complete caspase-3/-7 and caspase-9 inhibition, although preventing peculiar events such as Bcl-2 and Apaf-1 proteolytic cleavage, fails to spare more canonical proteic targets and, overall, to decrease the entity of apoptotic cell Role of calpain in cisplatin-induced apoptosis and p53 status B Del Bello et al death (Del Bello et al., 2001 . Furthermore, here we show that caspase-3/-7 inhibition does not prevent calpain activity, rather an increase is observed. On the contrary, calpain inhibition, as obtained by three different molecules (MDL 28170, calpeptin and PD 150606) , affords a significant decrease (or more likely a delay) of cell detachment and caspase-3/-7 activity. The former event, in our experience strictly proportional to the amount of apoptotic nuclei, proves to be not restricted to one specific cellular context, as it occurs in a number of different melanoma cell lines. PD 150606 (Ca 2 þ -binding domain inhibitor) is less effective than MDL 28170 and calpeptin (active site inhibitors) for both apoptosis protection and calpain activity inhibition. This result, which is quite common in the literature, further suggests that in our model different mechanisms, other than Ca 2 þ -imbalance, are mainly involved in calpain activation. The observed decrease of caspase-3/-7 activity is not accompanied by changes in the activation patterns of caspase-3, -7 and -9 (not shown), thus ruling out the possibility of a direct and unspecific effect of calpain inhibitors on procaspases processing. Few calpain-mediated mechanisms have been reported in various experimental settings, which could explain both the cross-talk between calpains and caspases and the protection of cell death obtained by calpain inhibitors: (i) release of the X-linked inhibitor of apoptosis (XIAP) antagonist Smac/DIABLO (Gorka et al., 2004) and XIAP proteolysis (Kobayashi et al., 2002) , (ii) cleavage and release of AIF (apotosisinducing factor) from mitochondria (Polster et al., 2005) , (iii) Bax cleavage (Wood et al., 1998) and (iv) Bid cleavage (Mandic et al., 2002) . In the present paper, we suggest a novel upstream mechanism involving p53 in melanoma cells. The p53 protein is induced/activated in response to DNA-damaging agents, including cisplatin (Siddik, 2003) . As a sequence-specific transcription activator, p53 triggers pathways leading to cell cycle arrest, DNA repair or apoptosis (Gottlieb and Oren, 1996; Ko and Prives, 1996) . Here we show that under cisplatin treatment, p53 levels are elevated over control cells early and prior to death commitment, as seen for calpain activation. Consistent with the hypothesis that calpain acts upstream of p53, as also demonstrated in camptothecin-treated neuronal cells (Sedarous et al., 2003) , under calpain inhibition we observe, first, an attenuated p53 upregulation and, second, a decreased amount of apoptotic cells along with a decreased caspase-3/-7 activity. For the first point, this finding is in contrast with a few reports showing that calpain inhibition upregulates p53 levels and induces apoptosis in proliferating cell systems (Atencio et al., 2000; Zhu and Uckun, 2000) ; on the other hand, regardless from any possible involvement of p53, an anti-apoptotic effect of calpain inhibition has been widely demonstrated (Neumar et al., 2003, and herein) . To assign a definitive role to calpain in p53 up-regulation, additional studies are required. However, some mechanisms can be envisaged, including nuclear factor (NF-kB) activation (E Maellaro, unpublished observations; Schaecher et al., 2004) which in turn could transcriptionally activate p53 (Wu and Lozano, 1994; Sedarous et al., 2003) , or different mechanisms acting on p53 protein stabilization through a direct or indirect proteolytic interference with the major negative p53 regulators MDM2 and MDMX (Chen et al., 1997; Gentiletti et al., 2002) . The second point is how calpain inhibition protects from cisplatininduced apoptosis. We demonstrate that p53 is downregulated along with a decrease of caspase-3/-7 activity; however, as any protection against apoptosis was never observed under complete caspase-3/-7 inhibition by DEVD-CHO, a parallel mechanism different from the apoptosome formation may be the crucial p53-mediated event explaining the protection from apoptosis by calpain inhibition. In addition to p53 modulation, such protection can also derive from the sparing of calpainspecific critical substrate(s), not shared with the effector caspase-3 and -7.
Essentially in in vitro models, p53 has been proved to be a proteolytic substrate of calpain (Gonen et al. 1997; Kubbutat and Vousden, 1997; Pariat et al., 1997) , forming fragments of different molecular weight, including p50, p45 and p35 peptides. A novel finding demonstrated in vivo in our experimental system is represented by the p53 proteolysis in late apoptotic cells, producing a peptide of E26 kDa. Such a proteolysis is efficiently rescued by calpain inhibitors, suggesting that calpain, by a direct or indirect mechanism, is responsible for this specific p53 degradation. As calpains recognize structural determinants (rather than specific sequence motifs) on their proteic targets, different conformational mutants (p53 mutant Y236H, in our cell line) (Maellaro et al., 2000) and, even more, post-translational modifications can affect the rate and the mode of p53 proteolysis. Thus, future studies will be aimed to elucidate whether the susceptibility to proteolysis of p53 could depend on its ubiquitination and/or phosphorylation status, as suggested for p53 degradation following phosphorylation by c-Jun N-terminal kinase (JNK) (Wang and Friedman, 2000) . A further posttranslational event worth to exploring is the oxidative modification of p53 tertiary structure (Biswas et al., 2006) , potentially occurring in our experimental model where glutathione, a major antioxidant defence, is strongly depleted.
In conclusion, the present study indicates that, in cisplatin-induced apoptosis of melanoma cells, calpain is activated upstream to effector caspases; such an activation is independent from Ca 2 þ imbalance, and plays a major role in cell death. The protective/delaying effect against apoptosis afforded by calpain inhibitors appears to be related to an early downregulation of p53 levels; the contribution of calpain in p53 upregulation seems to be nullified at later times when calpain, along with other proteases, targets p53 for its breakdown.
Materials and methods
Cell culture and treatments
The human metastatic melanoma cell line Me665/2/21 was cultured in Rosewell Park Memorial Institute (RPMI) 1640
Role of calpain in cisplatin-induced apoptosis and p53 status B Del Bello et al medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% heat-inactivated fetal calf serum (Invitrogen), 2 mM l-glutamine (Sigma-Aldrich, Milano, Italy) and 50 mg/l gentamycin, at 371C, under 95% air: 5% CO 2 in a humidified atmosphere. Cells were routinely harvested by phosphatebuffered saline (PBS)-ethylene diamine tetra acetic acid (EDTA) (0.2 g/l) and reseeded before reaching confluence. In selected experiments, we used four different unselected cell lines, also derived from metastases of human melanomas: Me665/2/60, HT-144 and SK-Mel-28, cultured in standard conditions, as described previously (Maellaro et al., 2003) . Cells were treated for different experimental times with cisplatin CDDP (Sigma) at the concentration of 1 mg/ml, unless otherwise stated, at the constant ratio of 20 nmol/10 6 cells. Calpain inhibitors MDL-28170 (Z-Val-Phe-aldehyde) (Sigma) and calpeptin (Z-Leu-norLeu-aldehyde) (Calbiochem, La Jolla, CA, USA), and caspase-3/-7 inhibitor ac-DEVD-CHO (ac-Asp-Glu-Val-Asp-aldehyde) (Alexis Corp., Lausen, Switzerland) were added (50 mM each) to culture medium at 0 time; calpain inhibitor PD 150606 (Calbiochem) was added at 0 time and at 24 h of incubation (60 mM each time); the cell permeable calcium chelator BAPTA-AM (Molecular Probes, Eugene, OR, USA) (2 mM) was added to cultured cells at 24 h. All compounds were left until the end of the experiment. For cisplatin-treated samples, we harvested and analysed the population of still adhering cells collectively with or separately from the population of detached cells, as specified in each figure legend.
Fluorogenic assay for caspases-3/-7 activity
The assay was performed in cell lysate as described previously (Del Bello et al., 2004) , using the preferred tetrapeptide ac-DEVD-AMC (50 mM). Cleavage of the fluorogenic substrate (as measured by AMC release) was monitored by a fluorescence spectrophotometer (excitation/emission wavelengths: 380/460 nm). Caspase activity was expressed as arbitrary units of fluorescence (AUFs)/min/mg protein.
Fluorogenic assay for calpain activity Calpain activity was measured in intact cells by using two different fluorescent substrates: N-succ-Leu-Tyr-AMC (Sigma) and the more cell-permeable t-Boc-Leu-Met-CMAC (Molecular Probes), essentially according to Rosser et al. (1993) . In brief, control and treated cells were harvested by PBS-EDTA (0.2 g/l), washed in PBS and resuspended in Krebs-RingerHepes assay buffer (115 mM NaCl, 1 mM KH 2 PO 4 , 2mM CaCl 2 , 5 mM KCl, 1.2 mM MgCl 2 , 25 mM Hepes buffer, pH 7.4) at the concentration of 3 Â 10 5 cells in 1.8 ml. The cell suspension was maintained under a gentle stirring in the cuvette, and the enzymatic reaction was initiated by adding 150 mM Succ or 10 mM BOC. Cleavage of the fluorogenic substrates was recorded as AMC release in a fluorescence spectrophotometer (excitation/emission wavelengths: 380/ 460 nm), and the cleavage rate was determined in the linear portion of the progress curve (15-20 min following the first 5 min). Calpain activity was expressed as AUF/min/10 6 cells.
Western blot analyses
Aliquots (40-60 mg protein) of cell lysates used for caspase activity were subjected to sodium dodecyl sulfate-polyacryamide gel electrophoresis 12% for calpain small subunit, or 10% for m-calpain large subunit and p53, followed by electroblotting to nitrocellulose membrane (Protan BA 85, 
GSH determination
The intracellular concentration of GSH was measured essentially according to Sedlak and Lindsay (1966) . Briefly, 10 6 cells were harvested, washed and carefully lysed in 350 ml of cold 5% trichloroacetic acid. Aliquots of the acidic supernatants were assayed with the Ellman's reagent 5,5 0 -dithiobis (2-nitrobenzoic acid) (DTNB). GSH concentration was calculated as absorbance at 412 nm, using a molar extinction coefficient of 13 100. The protein content was measured in the acid-insoluble pellet, according to Lowry et al. (1951) .
[Ca 2 þ ] measurements Cells were loaded with the fluorescent calcium indicator Fura-2 acetoxymetyl ester (Fura-2-AM) to evaluate changes of cytosolic free calcium concentration [Ca 2 þ ] c , as described previously (Gamberucci et al., 1994) . Briefly, after Fura-2-AM (3 mM) loading for 20 min at 371C, cells were maintained in medium (140 mM NaCl, 5.4 mM KCl, 1 mM MgCl 2 , 1mM CaCl 2 , 10 mM glucose, 15 mM Hepes buffer, pH 7.4) containing 200 mM sulfinpyrazone to minimize the leakage of intracellular Fura-2. Aliquots were rapidly centrifuged and resuspended in fresh medium with no added Ca 2 þ to give 1 Â 10 6 cells/ml. Ca 2 þ movements were evaluated by a calcium free/calcium readmission protocol: cytosolic Ca 2 þ basal levels were obtained by adding Na-ethylene glycol bis(B-amino ethyl ether)-N,N,N 0 ,N 0 tetraacetic acid (EGTA) to nominally Ca 2 þ -free medium to eliminate possible calcium traces; reticular Ca 2 þ was evaluated after depletion of the stores with Thapsigargin, a SERCA (sarcoplasmic-endoplasmic reticulum Ca 2 þ ATP-ase) inhibitor; Ca 2 þ entry through plasma membrane channels was finally evaluated by readmitting CaCl 2 . Fluorescence was measured in cuvette at 301C under continuous stirring, with a Varian Cary Eclipse fluorescence spectrophotometer (excitation: 340 and 380 nm; emission: 510 nm). Calcium concentration changes are reported as 'ratio 340/380', which represents the ratio between the fluorescence values of Fura-2-Ca 2 þ complex (detected at wavelengths 340/ 510 nm) and the fluorescence values of free Fura-2 (detected at wavelengths 380/510). Values of [Ca 2 þ ] i were calculated by the formula reported in Gamberucci et al. (1994) .
